Neuphoria Therapeutics (STU:B1N0) Margin of Safety % (DCF FCF Based) : N/A (As of Mar. 29, 2025)

View and export this data going back to 2021. Start your Free Trial

What is Neuphoria Therapeutics Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Neuphoria Therapeutics's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

Competitive Comparison of Neuphoria Therapeutics's Margin of Safety % (DCF FCF Based)

For the Biotechnology subindustry, Neuphoria Therapeutics's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neuphoria Therapeutics's Margin of Safety % (DCF FCF Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neuphoria Therapeutics's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Neuphoria Therapeutics's Margin of Safety % (DCF FCF Based) falls into.

Save Embed

;

Save Embed

;

Neuphoria Therapeutics Margin of Safety % (DCF FCF Based) Related Terms

Thank you for viewing the detailed overview of Neuphoria Therapeutics's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Neuphoria Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuphoria Therapeutics Inc (STU:B1N0) » Definitions » Margin of Safety % (DCF FCF Based)

Comparable Companies

Traded in Other Exchanges

NEUP:USA

Address

100 Summit Dr, Burlington, MA, USA, 01803

Website

https://www.bionomics.com.au

Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.

Neuphoria Therapeutics Headlines

No Headlines